NeurologyLive® Clinician of the Month Spotlight: Danielle Andrade, MD, MSc, FRCPC

Commentary
Article

As part of our monthly clinician spotlight, NeurologyLive® highlighted seizure disorder expert Danielle Andrade, MD, MSc, FRCPC, director of the Adult Genetic Epilepsy Program at the University of Toronto.

Danielle Andrade, MD, MSc, FRCPC  (Credit: Dravet Syndrome Foundation)

Danielle Andrade, MD, MSc, FRCPC

(Credit: Dravet Syndrome Foundation)

Neurologists are highly trained medical professionals who play a critical role in the healthcare system in helping patients of all ages manage their conditions that can affect every aspect of their lives. Each month, NeurologyLive® shines a spotlight on the work of one neurologist, highlighting contributions to their specific field.

Dravet syndrome (DS), formerly known as severe myoclonic epilepsy in infancy, is an epileptic encephalopathy that manifests with prolonged seizures in the first year of life. These seizures are often triggered by fever or illness and are initially mistaken for febrile seizures. Prior studies have shown that accurate diagnosis and follow-up are typically delayed, as early EEGs are normal and neuroimaging has showed no structural abnormalities.

Although early development in patients with DS appears normal, signs of regression typically emerge in the second year of life, accompanied by convulsive status epilepticus, alternating hemiconvulsions, and myoclonic seizures. Research shows that genetic testing can confirm the diagnosis by identifying mutations in the SCN1A gene. Additionally, early recognition and appropriate management with specific anticonvulsants as well as a tailored treatment plan for patients with DS can reduce their seizure frequency and overall improve long-term developmental outcomes.

In honor of Dravet Syndrome Awareness Month and Dravet Syndrome Awareness Day, Danielle Andrade, MD, MSc, FRCPC, professor of medicine, director of the Adult Genetic Epilepsy Program and medical director of the Epilepsy Program at the University of Toronto, had a conversation with NeurologyLive to discuss how she balances her responsibilities between patient care, teaching, and research. She also talked about the advancements in genetic research that have had the most significant impact on your practice. Furthermore, Andrade described a case where precision therapy significantly improved a patient's quality of life.

Clinical Facts About Dravet Syndrome

  • Studies report that 1 in 20,000 to 1 in 40,000 patients have DS and 3% to 8% of children who had their first seizure by 12 months old may have Dravet.
  • Seizures that last more than 10 minutes, seizures that occur on one side of the body, and ones triggered by a warm water bath in children under 12 months old are signs of a DS diagnosis.
  • The most common gene mutation linked to Dravet is in a gene called SCN1A. When this gene isn’t working properly, it causes the sodium channels in the brain to not work correctly.
REFERENCES
1. Dravet Syndrome. Epilepsy Foundation. Accessed June 21, 2024. https://www.epilepsy.com/what-is-epilepsy/syndromes/dravet-syndrome

NeurologyLive: What are some of the main responsibilities you have in your role as a neurologist?

As a neurologist focused on adults with genetic epilepsies, one of my main concerns is seizure control. We always strive to obtain the best seizure control with the minimal or no adverse effects of treatment. That can sometimes be very difficult, especially in patients with developmental and epileptic encephalopathies, which are often drug-resistant. In addition to exploring the frequency and severity of seizures, we want to understand their possible triggers as well as overall quality of life.

Could you describe a typical day in your work as a neurologist?

One of my clinical responsibilities is with outpatients that I see in our Adult Genetic Epilepsy (AGE) clinic. Usually, there are fellows or residents who are learning how to become the best neurologist/epileptologist possible. So, in addition to the care we deliver to patients, I am always teaching someone. I also care for patients admitted to the Epilepsy Monitoring Unit, where they have video-EEG for 24 hours per day, several days in a row. So, part of my clinical work is to report continuous video-EEG, teaching fellows, and residents along the way.

We also do clinical research, so all that patients say, the symptoms they present and their response to treatment needs to be precisely documented, such that we can learn from each patient in a way that we can eventually help more people with genetic epilepsies. When you have a very specialized clinic, you always have many scientific questions, that if answered would improve patients' health. So, part of my work is dedicated to research, including writing grants, working with graduate students, research personnel, and writing up scientific papers. There is also the administrative part of working in a large university hospital.

What motivated you to pursue a career in neurology, and when did you make this decision?

When I first learned neuroanatomy in medical school I knew I wanted to work as a neurologist. Nothing fascinates me more than the brain. During my neurology residency, I started to realize that genetics was a big part of understanding neurological diseases and eventually could be used to deliver precision therapies. That led me to pursue graduate studies in the molecular genetics of progressive myoclonus epilepsies. After that work, the natural next step was a fellowship in epilepsy, which then really "completed" my education, although we are always learning.

What do you find most rewarding about your work as a neurologist?

The ability to combine clinical care and research in a way that can really make a difference in a patient's live. I find it very rewarding to be able to look at all symptoms, study them individually, collaborate with colleagues that are experts in other areas and learn things about my patients that I had not previously observed. Then we reconstruct all findings and can see the patient as a whole person again. Only then, we can properly apply the newest research and find better treatments.

What are some of the biggest challenges you face in your role? 

Although we know now so much more than we did just a few years ago, there's so much more to learn and discover so that patients' can truly benefit from all the technology and research.

Is there something that you wish more patients and clinicians at your clinic understood about the field?

I believe it is important to remind everyone that updating genetic investigations is extremely important. Some of the patients with genetic epilepsies now can be treated with precision therapy and some are candidates for gene therapy trials.

In addition to your work as a neurologist, what other hobbies or interests do you have outside of the clinic?

I love working with plants, have lots of them around me. I also love spending time with good friends and good food.

Know a clinician who you'd like to see highlighted?
Click here to send us a nomination

Andrade recently sat down with NeurologyLive in an interview to discuss how the medical community can better support younger patients with epilepsy in their teens during the transition period from pediatric to adult care. She also shared some examples of specific difficulties that patients may face when essential healthcare services are lost during the transfer. Additionally, Andrade spoke about the ways neurologists who see adult patients can enhance their understanding of the broader health issues faced by young adult patients with epilepsy beyond seizures.

Transcript edited for clarity. Click here for more coverage on epilepsy.

REFERENCES
1. Millichap JJ, Koh S, Laux LC, Nordli DR Jr. Child Neurology: Dravet syndrome: when to suspect the diagnosis. Neurology. 2009;73(13):e59-e62. doi:10.1212/WNL.0b013e3181b9c880
Related Videos
Amaal Starling, MD
 Tracey Milligan, MD
Agne Straukiene, MD
Michael Soileau, MD, FAAN
Patricia Clark, CNP
 Eric Olson, MD
R. Scott Turner, PhD, MD, FANA, FAAN
Video 5 - 5 KOLs are featured in "Managing Clinical Stability in Adults Spinal Muscular Atrophy Patients"
© 2024 MJH Life Sciences

All rights reserved.